FDA Inspection 1240231 — BrightGene Pharmaceutical Co., Ltd.
The FDA completed an inspection of BrightGene Pharmaceutical Co., Ltd. on Apr 26, 2024 in Suzhou. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions or practices were found, but the agency is not prepared to take or recommend any administrative or regulatory action). Product area: Drugs.
Inspection Details
- Classification
- Voluntary Action Indicated (VAI)
- End Date
- Apr 26, 2024
- Fiscal Year
- 2024
- Product Type
- Drugs
- Project Area
- Drug Quality Assurance
- Location
- Suzhou (China)